Literature DB >> 29157402

Effective Utilization of MRI in the Diagnosis and Management of Multiple Sclerosis.

Antonio Giorgio1, Nicola De Stefano2.   

Abstract

MRI is the most important tool for diagnosis and management of patients with multiple sclerosis (MS). MRI shows high sensitivity for detection of white matter lesions in the central nervous system and specificity for lesion dissemination in space and time. MRI is also used for tracking disease activity, prognostic evaluation, and monitoring the efficacy and safety of disease-modifying treatments. Nonconventional MRI measures (eg, brain atrophy) and quantitative measures of advanced MRI can capture features of MS beyond WM lesions but are not currently implemented in clinical practice. Consensus guidelines on standardized MRI acquisition protocol have been recently published.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrophy; Diagnosis; Disease-modifying treatment; Lesions; MRI; Management; Multiple sclerosis; Standardized MRI protocol

Mesh:

Year:  2018        PMID: 29157402     DOI: 10.1016/j.ncl.2017.08.013

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  8 in total

Review 1.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

2.  Brain Pathology in Multiple Sclerosis with High-Field-Strength MR Spectroscopic Imaging.

Authors:  Peter B Barker
Journal:  Radiology       Date:  2022-01-04       Impact factor: 11.105

3.  High-resolution quantitative MRI of multiple sclerosis spinal cord lesions.

Authors:  Amy R McDowell; Natalia Petrova; Daniele Carassiti; Marc E Miquel; David L Thomas; Gareth J Barker; Klaus Schmierer; Tobias C Wood
Journal:  Magn Reson Med       Date:  2022-01-11       Impact factor: 3.737

4.  Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

Authors:  H N Beadnall; C Wang; W Van Hecke; A Ribbens; T Billiet; M H Barnett
Journal:  Ther Adv Neurol Disord       Date:  2019-01-25       Impact factor: 6.570

5.  Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain.

Authors:  Lina Anderhalten; Rafaela V Silva; Anna Morr; Shuangqing Wang; Alina Smorodchenko; Jessica Saatz; Heike Traub; Susanne Mueller; Philipp Boehm-Sturm; Yasmina Rodriguez-Sillke; Désirée Kunkel; Julia Hahndorf; Friedemann Paul; Matthias Taupitz; Ingolf Sack; Carmen Infante-Duarte
Journal:  Invest Radiol       Date:  2022-04-21       Impact factor: 10.065

6.  Magnetic Resonance Imaging and Clinical Features of the Demyelinating Degeneration of White Matter in Young Patients.

Authors:  Jian Li; Yi-Ming Zhao
Journal:  Int J Gen Med       Date:  2021-07-05

7.  Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years.

Authors:  Irene Pulido-Valdeolivas; Magí Andorrà; David Gómez-Andrés; Kunio Nakamura; Salut Alba-Arbalat; Erika J Lampert; Irati Zubizarreta; Sara Llufriu; Eloy Martinez-Heras; Elisabeth Solana; Nuria Sola-Valls; María Sepulveda; Ana Tercero-Uribe; Yolanda Blanco; Anna Camos-Carreras; Bernardo Sanchez-Dalmau; Pablo Villoslada; Albert Saiz; Elena H Martinez-Lapiscina
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

8.  Automatic segmentation of white matter hyperintensities: validation and comparison with state-of-the-art methods on both Multiple Sclerosis and elderly subjects.

Authors:  Philippe Tran; Urielle Thoprakarn; Emmanuelle Gourieux; Clarisse Longo Dos Santos; Enrica Cavedo; Nicolas Guizard; François Cotton; Pierre Krolak-Salmon; Christine Delmaire; Damien Heidelberg; Nadya Pyatigorskaya; Sébastian Ströer; Didier Dormont; Jean-Baptiste Martini; Marie Chupin
Journal:  Neuroimage Clin       Date:  2022-01-10       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.